EU Pharma Strategy Will Remove Barriers And Bolster Competition
Proposals Promise ‘Targeted Policies’ To Boost Generics And Biosimilars
The European Commission’s newly-published Pharmaceutical Strategy features a range of proposals related to generics and biosimilars, including “targeted policies” to improve competition, remove barriers and increase uptake.
You may also be interested in...
Medicines For Europe and Czech association CAFF demand EU and national reforms to help drug makers ensure supply and patient access, particularly in Central and Eastern Europe.
Teva has called for action from European leaders to address the threat of an essential medicines industry “exodus” from the region, suggesting that the continent is facing a losing battle against China and India that has led to the migration of vital manufacturing assets.
The recent statement by the EMA and HMA affirming the interchangeability of biologics and biosimilars has given a boost to Europe’s biosimilars industry ahead of key legislative reforms, heard delegates to Medicines for Europe’s 18th Biosimilar Medicines Conference in Brussels.